Cambridge Healthtech Institute’s 2nd Annual

Targeting Fibrosis

Developing Medical Therapies for Fibrotic Diseases

September 17-18, 2020


CHI’s 2nd Annual Targeting Fibrosis conference will follow the model of last year’s successful launch by covering a mix of drug discovery successes and development challenges in the field of fibrosis. Presentations will focus on new molecular entities being targeted by small molecules, biologics, or newer modalities that show potential for reducing organ fibrosis. Most of the compounds with clinical success are in the lung, so much of the conference will focus on that organ. However, fibrosis of the kidney, skin, and other organs may also be covered to assess common scarring mechanisms and molecular pathways. Liver fibrosis will mostly be covered in the preceding NASH conference at this Discovery on Target event. We hope you can join us to share progress and discuss future directions in the field of fibrosis, an area whose disease burden is steadily increasing as the population of elderly, and thus, chronic disease and inflammation, rises.

Preliminary Agenda


Small-Molecule Inhibitors Targeting Nox4 for the Treatment of Lung Fibrosis

Louise Hecker, PhD, Associate Professor, Department of Medicine, University of Arizona; Founder, Fibronox

Cell Specific Roles of Integrin Alpha V in Inflammation and Fibrosis

Kevin Hart, PhD, Principal Scientist, Inflammation, Pfizer

ROCK Updates and New Fibrosis Targets

Masha Poyurovsky, PhD, Vice President, Discovery Biology, Kadmon Corporation, LLC

Talk Title to be Announced

Ji Zhang, PhD, Scientist, Cardiorenal Metabolic & Ophthalmologic Drug Discovery, Merck Research Labs


Translational Trends in Fibrosis Drug Discovery

Carolyn Cuff, PhD, Senior Director, Translational Immunology, Immunology Discovery, AbbVie Bioresearch Center


Translational Pharmacology of TD139, an Inhaled Small Molecule Galectin-3 Inhibitor for the Treatment of IPF

Rob Slack, PhD, Director of Pharmacology, Galecto, Inc.

Targeting Integrins for Lung and Other Organ Fibrosis

Katerina Leftheris, PhD, Vice President, Chemistry, Pliant

Characterization of IDL-2965, a Clinical Stage Integrin Antagonist for the Treatment of IPF

Karl Kossen, PhD, Senior Vice President, Translational Science, Indalo Therapeutics


Please click here to return to the agenda for Targeting NASH

For more details on the conference, please contact:

Anjani Shah, PhD

Senior Conference Director

Cambridge Healthtech Institute

Phone: (+1) 781-247-6252



For partnering and sponsorship information, please contact:

Rod Eymael

Manager, Business Development

Cambridge Healthtech Institute

Phone: (+1) 781-247-6286